Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS.
Front Immunol
; 12: 738697, 2021.
Article
in En
| MEDLINE
| ID: mdl-34659231
ABSTRACT
The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted the urgent need for novel therapies. Cell-based therapies, primarily using mesenchymal stromal cells (MSCs), have demonstrated safety and potential efficacy in the treatment of critical illness, particularly sepsis and acute respiratory distress syndrome (ARDS). However, there are limited preclinical data for MSCs in COVID-19. Recent studies have shown that MSCs could decrease inflammation, improve lung permeability, enhance microbe and alveolar fluid clearance, and promote lung epithelial and endothelial repair. In addition, MSC-based therapy has shown promising effects in preclinical studies and phase 1 clinical trials in sepsis and ARDS. Here, we review recent advances related to MSC-based therapy in the context of sepsis and ARDS and evaluate the potential value of MSCs as a therapeutic strategy for COVID-19.
Key words
Full text:
1
Collection:
01-internacional
Health context:
4_TD
Database:
MEDLINE
Main subject:
Mesenchymal Stem Cell Transplantation
/
Cell- and Tissue-Based Therapy
/
Cytokine Release Syndrome
/
COVID-19
Limits:
Humans
Language:
En
Journal:
Front Immunol
Year:
2021
Document type:
Article